Recap: Jazz Pharmaceuticals Q2 Earnings

Shares of Jazz Pharmaceuticals JAZZ decreased in after-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share rose 5.12% over the past year to $3.90, which beat the estimate of $3.42.

Revenue of $751,811,000 rose by 33.67% year over year, which beat the estimate of $735,620,000.

Guidance

Jazz Pharmaceuticals Sees FY21 Sales $3.02B-$3.18B Vs. $3.11B Est., EPS $13.40-$14.70 Vs. $14.45 Est.

Conference Call Details

Date: Aug 03, 2021

Time: 04:30 PM

ET Webcast URL: https://edge.media-server.com/mmc/p/amfe6pc3

Technicals

52-week high: $189.00

Company's 52-week low was at $107.59

Price action over last quarter: down 0.60%

Company Profile

Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and indications in neuroscience and hematology-oncology. Jazz's product portfolio includes its lead drug, Xyrem, for narcolepsy, Sunosi for improving wakefulness in patients with excessive daytime sleepiness, Defitelio for severe veno-occlusive disease after stem cell transplant, Vyxeos for acute myeloid leukemia, and Zepzelca for small cell lung cancer.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsBZI-Recaps
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!